Informed consent for low-risk thyroid cancer-Reference-Cited by-同舟云学术

Informed consent for low-risk thyroid cancer

Published:2016-05 Issue:2 Volume:3 Page:131-142
ISSN:2045-0869
Container-title:International Journal of Endocrine Oncology
language:en
Short-container-title:International Journal of Endocrine Oncology

Author:

Rosenthal M Sara¹,Angelos Peter²,Bible Keith³,Fassler Cheryl Ann⁴,Finder Stuart⁵,Greene Loren Wissner⁶,Tulchinsky Mark⁷

Affiliation:

1. Departments of Internal Medicine, Pediatrics & Behavioral Science, Program for Bioethics, University of Kentucky, Lexington, KY, USA

2. Department of Surgery, University of Chicago, MacLean Center for Clinical Medical Ethics, Chicago, IL, USA

3. Mayo Clinic, Rochester, MN, USA

4. Heritage Medical Associates, P.C., Nashville, TN, USA

5. Center for Healthcare Ethics, Cedars-Sinai Medical Center, Los Angeles, CA, USA

6. Division of Endocrinology & ObGyn, and Associate Faculty, Department of Population Health, Division of Medical Ethics, New York University School of Medicine, New York, NY, USA

7. Division of Nuclear Medicine, Department of Radiology, Penn State University, Milton S. Hershey Medical Center, Hershey, PA, USA

Abstract

Significant barriers to informed consent surround the clinical management of adult patients with well-differentiated thyroid cancer. The literature reveals lack of disclosure surrounding clinical equipoise; confusing and conflicting terminology; and an insufficient number of prospective trials with proper ethical oversight. We provide guidance for valid consent to treatment in this population, and propose stipulative definitions for a variety of terms used in this context. Three critical areas are addressed: surgical management, radioactive iodine management and nonvalidated practice. Sound ethical frameworks for valid consent in patients with low-risk thyroid cancer include consent to observational (or ‘active surveillance’) research protocols, consent to nonvalidated practice and consent when there are opposing standards of care due to insufficient data and disagreement among the community of experts.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Endocrinology,Oncology,Endocrinology, Diabetes and Metabolism

Link

https://www.futuremedicine.com/doi/pdf/10.2217/ije-2015-0010

Reference70 articles.

1. Equipoise and the Ethics of Clinical Research

2. US Department of Health and Human Services. “Code of Federal Regulations – Title 45 Public Welfare CFR 46” – Title 45 Public Welfare CFR 46.116(a). www.hhs.gov/ohrp/humansubjects/commonrule/.

3. Office of Human Subject Protection. Proposed Rules 53933. Federal Register 80(173) (2015).

4. Office of Human Subject Protections. Draft Guidance on Disclosing Foreseeable Risks in Research Evaluating the Standards of Care. www.hhs.gov/ohrp/newsroom/rfc/comstdofcare.html.

5. Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer;Current Pharmaceutical Design;2020-09-17

2. Contemporary considerations in adjuvant radioiodine treatment of adults with differentiated thyroid cancer;International Journal of Cancer;2020-05-09

3. Research ethics dilemmas in thyroid disease;Current Opinion in Endocrinology & Diabetes and Obesity;2018-10

4. Improving the Informed Consent Process in Hematopoietic Cell Transplantation: Patient, Caregiver, and Provider Perspectives;Biology of Blood and Marrow Transplantation;2018-01

5. A Republican Argument Against Nudging and Informed Consent;HEC Forum;2017-12-30